Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin’s lymphoma
暂无分享,去创建一个
[1] Ho-Jin Shin,et al. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.
[2] Philippe Bertrand,et al. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.
[3] S. Mirzaei,et al. Prognostic significance of the standardized uptake value of pre-therapeutic 18F-FDG PET in patients with malignant lymphoma , 2011, Medical oncology.
[4] Seong-Jang Kim,et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.
[5] Dimitris Visvikis,et al. Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Y. Oki,et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma , 2011, International journal of hematology.
[7] Florent Tixier,et al. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[8] M. Juweid. FDG-PET/CT in lymphoma. , 2011, Methods in molecular biology.
[9] A. Alavi,et al. Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment , 2011, Molecular Imaging and Biology.
[10] S. Fujita,et al. [Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by 18F-FDG PET/CT]. , 2010, Kaku igaku. The Japanese journal of nuclear medicine.
[11] H. Mak,et al. Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification , 2010, Nuclear medicine communications.
[12] Maximilien Vermandel,et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[13] R. Boellaard. Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.
[14] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[15] A. Alavi,et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET , 2008, Nuclear medicine communications.
[16] F. Pons,et al. Utilidad de la tomografía por emisión de positrones/ tomografía computarizada (PET/TC) en el estudio de extensión en pacientes con linfoma B difuso de células grandes , 2007 .
[17] Emmanuel Itti,et al. Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.
[18] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. López-Guillermo,et al. [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma]. , 2007, Medicina clinica.
[20] A. Nagler,et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.
[22] E. Yoshikawa,et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[23] J. Itami,et al. FDG-PET for predicting the prognosis of malignant lymphoma , 1994, Annals of nuclear medicine.
[24] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[25] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.